PIA
APLS

Piedmont Investment Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Piedmont Investment Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-627
Closed -$14K – 1107
2018
Q2 		$14K Buy
+627
New +$14.4K ﹤0.01% 1701

Other funds holding APLS

HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Piedmont Investment Advisors's APLS Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Apellis Pharmaceuticals (APLS) in Q3 2018, closing a stake of 627 shares — an estimated $14K sold.

Piedmont Investment Advisors first reported a position in APLS in Q2 2018 and held it in 1 quarter. The position peaked at $14K in Q2 2018. 79 funds tracked by Wall St. Rank hold APLS as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Apellis Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 627 Apellis Pharmaceuticals shares in Q3 2018, an estimated $14K.
  • Piedmont Investment Advisors first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Apellis Pharmaceuticals position peaked at $14K in Q2 2018.
  • 79 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.